Track BioNexus Gene Lab's total liabilities ($950K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
BioNexus Gene Lab (BGLC) currently reports a total liabilities of $950K as of June 2026. That compares with $1.9M in the prior-year period — down 50.1% year over year. Use the charts on this page to explore BioNexus Gene Lab's total liabilities history and peer comparisons.
BioNexus Gene Lab's total liabilities decreased from $1.9M to $950K — a 50.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
BioNexus Gene Lab reported $950K in total liabilities as of June 2026. That compares with $1.9M in the prior-year period — down 50.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $950K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioNexus Gene Lab, and consider following BGLC for alerts when major investors trade the stock.